Yao 2018.

Methods	Study design: Randomised clinical trial Study duration: April 2013 to March 2015 Duration of follow‐up: 2 years Setting: Hospital
Participants	Inclusion criteria: Diagnosed as HCC by pathology or images; willing to sign a written informed consent document Exclusion criteria: With serious diseases of other organs; abnormal haematopoietic and cardiac function Age (mean ± SD): TACE + RFA: 42.18 ± 5.31 years; TACE alone: 41.76 ± 5.62 years Male (n/total): TACE + RFA: 26/42; TACE alone: 25/42 Child‐Pugh Class (patients): Class A: TACE + RFA: 34; TACE: 33 Class B: TACE + RFA: 8; TACE: 9
Interventions	TACE + RFA group: TACE: Chemotherapeutic drugs: 5‐fluorouracil 0.75‐1 g, cisplatin 40‐60 mg, and epirubicin 10‐30 mg RFA: CT‐guided RFA TACE group: Chemotherapeutic drugs: 5‐fluorouracil 0.75‐1 g, cisplatin 40‐60 mg, and epirubicin 10‐30 mg
Outcomes	Serum level of AFP Tumour response Survival rate Adverse events
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.